Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:17318853rdf:typepubmed:Citationlld:pubmed
pubmed-article:17318853lifeskim:mentionsumls-concept:C0040732lld:lifeskim
pubmed-article:17318853lifeskim:mentionsumls-concept:C0087111lld:lifeskim
pubmed-article:17318853lifeskim:mentionsumls-concept:C0206754lld:lifeskim
pubmed-article:17318853lifeskim:mentionsumls-concept:C0023884lld:lifeskim
pubmed-article:17318853lifeskim:mentionsumls-concept:C1522484lld:lifeskim
pubmed-article:17318853lifeskim:mentionsumls-concept:C0036525lld:lifeskim
pubmed-article:17318853pubmed:issue3lld:pubmed
pubmed-article:17318853pubmed:dateCreated2007-3-5lld:pubmed
pubmed-article:17318853pubmed:abstractTextLiver transplantation can be a therapeutic option for individual patients with neuroendocrine tumors metastatic only to the liver. In this consecutive series of 15 patients (5 multivisceral and 10 orthotopic liver transplantations) with well-differentiated carcinoids, or endocrine pancreatic tumors, we allowed higher proliferation rate (Ki67 <10%), large tumor burden, and higher age than previous studies. Liver transplantation offered good relief of symptoms, long disease-free intervals, and potential cure in individual patients. The survival of grafts and patients compared well with transplantation for benign disease. The overall 5-year survival was 90%. The recurrence-free survival of both multivisceral and liver transplantation related to the time after transplantation (about 20% at 5 years) despite inclusion of patients with higher risk. In conclusion, the critical prognosticators for long-term outcome still remain to be defined. The experience with multivisceral transplantation for patients with endocrine tumors of the pancreatic head is still limited.lld:pubmed
pubmed-article:17318853pubmed:languageenglld:pubmed
pubmed-article:17318853pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:17318853pubmed:citationSubsetIMlld:pubmed
pubmed-article:17318853pubmed:statusMEDLINElld:pubmed
pubmed-article:17318853pubmed:monthMarlld:pubmed
pubmed-article:17318853pubmed:issn1527-6465lld:pubmed
pubmed-article:17318853pubmed:authorpubmed-author:AhlmanHåkanHlld:pubmed
pubmed-article:17318853pubmed:authorpubmed-author:WängbergBoBlld:pubmed
pubmed-article:17318853pubmed:authorpubmed-author:NilssonOlaOlld:pubmed
pubmed-article:17318853pubmed:authorpubmed-author:FrimanStyrbjö...lld:pubmed
pubmed-article:17318853pubmed:authorpubmed-author:JanssonSvante...lld:pubmed
pubmed-article:17318853pubmed:authorpubmed-author:OlaussonMicha...lld:pubmed
pubmed-article:17318853pubmed:authorpubmed-author:CahlinChristi...lld:pubmed
pubmed-article:17318853pubmed:authorpubmed-author:HerleniusGust...lld:pubmed
pubmed-article:17318853pubmed:copyrightInfo(c) 2007 AASLD.lld:pubmed
pubmed-article:17318853pubmed:issnTypePrintlld:pubmed
pubmed-article:17318853pubmed:volume13lld:pubmed
pubmed-article:17318853pubmed:ownerNLMlld:pubmed
pubmed-article:17318853pubmed:authorsCompleteYlld:pubmed
pubmed-article:17318853pubmed:pagination327-33lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:meshHeadingpubmed-meshheading:17318853...lld:pubmed
pubmed-article:17318853pubmed:year2007lld:pubmed
pubmed-article:17318853pubmed:articleTitleOrthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors.lld:pubmed
pubmed-article:17318853pubmed:affiliationSahlgrenska Transplant Institute, Sahlgrenska Academy, University of Göteborg, Göteborg, Sweden.lld:pubmed
pubmed-article:17318853pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:17318853pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17318853lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17318853lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17318853lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:17318853lld:pubmed